By

David Shaywitz

11
Nov
2019

Disruption, Fast and Slow

Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science VCs, writing in a superb recent article (a response to my previous TR post): “The most consistent thread that differentiates tech and life science VCs is their willingness to project new data onto an industry and imagine resultant...
Read More
5
Nov
2019

Tech VCs and Biotech VCs: Talking Past Each Other on AI Drug Discovery

[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture capitalists and biotech VCs, look at their respective views on AI applications for drug discovery. Many of the most prominent AI drug discovery startups boast exceptionally rich valuations, driven by the enthusiastic participation of tech...
Read More
18
Apr
2019

Life After Twitter

[Editor’s Note: David Shaywitz is a Palo Alto-based life science VC. He used to be active on Twitter. I asked him to share his reflections on leaving the platform–LT.] Quitting carbs last year was hard. Quitting Twitter this year has proved delightfully easy.  You might even want to try it for yourself. Twitter has tremendous upside. Most notably, it provides...
Read More